Michael Finney

Michael Finney has a diverse work experience in various companies and roles. In 2004, they founded Finney Capital and became the Managing Director. Michael also served as the Board Chair for Addition Therapeutics since June 2021. In 2007, they joined Vaxart Inc. as a Director and later became the CEO from July 2009 to October 2011. Michael has been the Board Chair of Thrive Bioscience, Inc. since November 2014. Michael also held positions as Director in S2 Genomics, seqWell Inc, Orion Genomics, and KaRNATeq since 2019, 2016, 1998, and 2019 respectively. Additionally, they served as the Board Chair for Sage Science since 2005. In 1999, they joined The Genome Partnership — AGBT as Director and Permanent Member, where they contributed to the organization of the AGBT Genomics meeting.

Michael Finney attended Tates Creek High School from 1973 to 1976. After completing high school, they went on to pursue their undergraduate studies at Harvard University from 1976 to 1980. At Harvard, they obtained a Bachelor of Arts (AB) degree in Biochemical Sciences. Following their undergraduate studies, Michael enrolled at the Massachusetts Institute of Technology (MIT) and pursued a Ph.D. in Biology from 1980 to 1987. Later, in 2015, they attended Stanford Law School, where they completed the Stanford Directors' College program.